Kidney Week

Abstract: FR-PO674

A Real-World Study on the Clinical Characteristics and Treatments of Complement-Mediated Kidney Diseases in China

Session Information

• Genetic Kidney Diseases: Cohort Studies - Genetic Associations and Diagnoses
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

• 1202 Genetic Diseases of the Kidneys: Non-Cystic

Authors

• Nie, Sheng, Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China

Sheng Nie, MD, PhD

• Zou, Qing, Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China

Qing Zou

• Zhou, Shiyu, Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China

Shiyu Zhou, MD

• Gao, Fei, Beijing Novartis Pharma. Co. Ltd, Shanghai, China

Fei Gao

• Zhang, Tianwei, Beijing Novartis Pharma. Co. Ltd, Shanghai, China

Tianwei Zhang

Background

Complement-mediated kidney diseases (CMKDs) are partly caused by overactivation of the alternative complement pathway, including C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), Immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), lupus nephritis (LN),among others. Despite their significant impact, studies on epidemiology and treatment patterns of CMKD in China are relatively scarce.

Methods

This is a retrospective, observational study using a nationwide real-world medical database in China (CRDS). Patients with CMKD were diagnosed at 24 regional central hospitals between 31 December 1998 until May 08, 2023. Descriptive analysis was performed on demographics, clinical characteristics and treatment approaches.

Results

A total of 57086 CMKD patients were included in the study, including 102, 843, 27456, 10988, and 17697 patients with C3G, aHUS, IgAN, MN and LN, respectively, with an average age of 46.8 years and 39.1% being males.
22.3% of CMKD patients had an eGFR<60ml/min/1.73m², 47.8% had low serum complement C3, and 18.5% had low serum C4. Among 11715 patients with kidney biopsy report, 69.1% was positive in C3 immunofluorescent staining and 17.5% was positive in C1q immunofluorescent staining (Table 1).
Among all CMKD patients, 35.4% received corticosteroids, followed by Renin-angiotensin system inhibitor (28.6%) and non-steroid immunosuppressants (22.2%) (Table 2), and the treatment pattern was significantly different among subtypes of CMKD.

Conclusion

The clinical characteristics and treatment of CMKDs varied among subtypes. The overall treatment proportion at baseline was low. This may suggest that the current treatment strategies for CMKDmay be insufficient, and treatment programs need further improvement.

Abbreviations: eGFR, estimated glomerular filtration rate.

Funding

• Commercial Support – Beijing Novartis Pharma. Co. Ltd